Latest from Perlmutter Cancer Center at NYU Langone

Leena Gandhi, MD, PhD, associate professor, Department of Medicine, director, Thoracic Medical Oncology Program, discusses the findings of cohort G of the KEYNOTE-021 trial that explored the combination of pembrolizumab (Keytruda) with carboplatin and pemetrexed for patients with advanced nonsquamous non-small cell lung cancer (NSCLC).
Findings from a clinical trial led by a researcher at NYU Langone's Perlmutter Cancer Center helped pave the way for the recent, accelerated approval by the US Food and Drug Administration of a highly effective immunotherapy as first-line treatment for patients with advanced bladder cancer who are not eligible for treatment with standard chemotherapy.
Arjun V. Balar, MD, assistant professor of medicine, Division of Hematology and Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the mature clinical trial results and biomarker findings of KEYNOTE-052, first-line pembrolizumab (Keytruda) in patients with cisplatin-ineligible advanced urothelial cancer, during the 2017 ASCO Annual Meeting.
Arjun V. Balar, MD, discusses the impact of the approval of pembrolizumab and other immunotherapy agents in urothelial carcinoma, as well as the next steps with these treatments.
Leena Gandhi, MD, PhD, director of the Thoracic Medical Oncology Program at NYU Langone School of Medicine, discusses sequencing challenges as well as emerging agents in the field of ALK-positive nonsmall cell lung cancer (NSCLC).
Leena Gandhi, MD, PhD, discusses emerging developments in the first-line treatment for patients with ALK-positive NSCLC, as well as novel agents emerging in the field.
Douglas Levine, MD, discusses a recent study in uterine carcinosarcoma and early steps toward developing therapeutic regimens.
Researchers at NYU Langone Medical Center are taking an approach that focuses on the unique metabolic adaptations of pancreatic cancer.
Publication Bottom Border
Border Publication